You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Chartwell Molecular Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHARTWELL MOLECULAR, and what generic and branded alternatives to CHARTWELL MOLECULAR drugs are available?

CHARTWELL MOLECULAR has eighty-eight approved drugs.

There are two tentative approvals on CHARTWELL MOLECULAR drugs.

Summary for Chartwell Molecular

US Patents:	0
Tradenames:	76
Ingredients:	74
NDAs:	88

Drugs and US Patents for Chartwell Molecular

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecular	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	065243-003	Aug 12, 2005		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	FURALAN	nitrofurantoin	TABLET;ORAL	080017-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	TEMOZOLOMIDE	temozolomide	CAPSULE;ORAL	203898-005	Feb 10, 2016		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	MORPHINE SULFATE	morphine sulfate	SOLUTION;ORAL	202309-001	Nov 25, 2015		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	MORPHINE SULFATE	morphine sulfate	SOLUTION;ORAL	201517-001	Jun 23, 2011		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	CETIRIZINE HYDROCHLORIDE	cetirizine hydrochloride	SOLUTION;ORAL	078876-001	May 11, 2012	AA	RX	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	ALBUTEROL SULFATE	albuterol sulfate	SYRUP;ORAL	078105-001	Dec 27, 2006	AA	RX	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell Molecular

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Molecular	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.